RECARBRIO

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
RECARBRIO
Generic name
IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS
Manufacturer
Merck Sharp & Dohme LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
be32f468-738b-40df-a425-591e12f65159
SPL ID
128d22eb-7136-4c07-8827-21a27fb99ede
Version
12
Effective date
2025-12-09
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:54:35
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta lactam drugs. Discontinue RECARBRIO immediately if a hypersensitivity reaction occurs. ( 5.1 ) Seizures and Central Nervous System Adverse Reactions: CNS adverse reactions such as seizures have been reported with imipenem/cilastatin, a component of RECARBRIO. If focal tremors, myoclonus, or seizures occur, evaluate patients, to determine whether RECARBRIO should be discontinued. ( 5.2 ) Increased Seizure Potential Due to Interaction with Valproic Acid: Concomitant use of RECARBRIO with valproic acid or divalproex sodium may reduce the serum concentration of valproic acid which may increase the risk of breakthrough seizures. Avoid concomitant use or consider alternative antibacterial drugs other than carbapenems. ( 5.3 , 7.2 ) Clostridioides difficile -Associated Diarrhea (CDAD): Has been reported with RECARBRIO. Evaluate if diarrhea occurs. ( 5.4 ) 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta lactams. Before initiating therapy with RECARBRIO, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams, and other allergens. If a hypersensitivity reaction to RECARBRIO occurs, discontinue the therapy immediately. RECARBRIO is contraindicated in patients with a history of severe hypersensitivity to any component of RECARBRIO [see Contraindications (4) ]. 5.2 Seizures and Other Central Nervous System (CNS) Adverse Reactions CNS adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, a component of RECARBRIO, especially when recommended dosages of imipenem were exceeded . These have been reported most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function . Anticonvulsant therapy should be continued in patients with known seizure disorders. If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether RECARBRIO should be discontinued. 5.3 Increased Seizure Potential Due to Interaction with Valproic Acid Concomitant use of RECARBRIO, with valproic acid or divalproex sodium may increase the risk of breakthrough seizures. Avoid concomitant use of RECARBRIO with valproic acid or divalproex sodium or consider alternative antibacterial drugs other than carbapenems [see Drug Interactions (7.2) ]. 5.4 Clostridioides difficile -Associated Diarrhea (CDAD) Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including RECARBRIO, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. 5.5 Development of Drug-resistant Bacteria Prescribing RECARBRIO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described in greater detail in the Warnings and Precautions section. Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Seizures and Other Central Nervous System Adverse Reactions [see Warnings and Precautions (5.2) ] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3) ] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4) ] Adult HABP/VABP Patients: The most frequently reported adverse reactions occurring in greater than or equal to 5% of patients treated with RECARBRIO were aspartate aminotransferase increased, anemia, alanine aminotransferase increased, diarrhea, hypokalemia, and hyponatremia. ( 6 ) Adult cUTI and cIAI Patients: The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients treated with imipenem/cilastatin plus relebactam 250 mg, the components of RECARBRIO, were diarrhea, nausea, headache, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, phlebitis/infusion site reactions, pyrexia, and hypertension. ( 6 ) Pediatric HABP/VABP, cUTI, and cIAI Patients: The most frequently reported adverse reactions occurring in greater than 3% of pediatric patients treated with RECARBRIO were vomiting, diarrhea, nausea, headache, phlebitis/infusion site reactions, and rash. To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients Overview of the Safety Evaluation of RECARBRIO in Adult Patients Safety was primarily evaluated in three active-controlled, double-blind trials in HABP/VABP, cUTI, and cIAI (Trials 1, 2, and 3, respectively). In the HABP/VABP trial (Trial 1), patients were treated with either RECARBRIO or piperacillin and tazobactam (4.5 grams). In the cUTI trial (Trial 2) and cIAI trial (Trial 3), patients in the treatment arms were treated with either imipenem 500 mg/cilastatin 500 mg and relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg (not an approved dose), and patients in the control arm were treated with imipenem 500 mg/cilastatin 500 mg plus placebo (IV normal saline). Across Trials 2 and 3, the mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days. Clinical Trial Experience in Adult Patients with HABP/VABP Trial 1 included 266 adult patients treated with RECARBRIO and 269 patients treated with piperacillin and tazobactam (4.5 grams) administered intravenously over 30 minutes every 6 hours. The mean age was 60 years, 43% of patients were 65 years of age and older, 31% were female and 22% had polymicrobial infection. The mean Acute Physiology and Chronic Health Evaluation (APACHE) II score was 15 and 48% of patients had an APACHE II score greater than or equal to 15 at baseline. Overall, 260 (49%) patients were ventilated at enrollment, including 194 (36%) patients with VABP and 66 (12%) patients with ventilated HABP. Clinical Trial Experience in Adult Patients with cUTI including, Pyelonephritis Trial 2 included 198 adult patients treated with imipenem/cilastatin and relebactam (99 patients each with imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg or relebactam 250 mg) and 100 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours. After a minimum of 4 days of IV therapy, patients could be switched to oral ciprofloxacin (500 mg daily every 12 hours) to complete the treatment course of 4 to 14 days total (IV plus oral), at the discretion of the investigator. The mean age was 56 years, 40% of patients were 65 years of age and older, 16% were 75 years of age and older, 50% were female, and approximately 18% had moderate to severe renal impairment. Clinical Trial Experience in Adult Patients with cIAI Trial 3 included 233 adult patients treated with imipenem/cilastatin plus relebactam (116 subjects with imipenem 500 mg/cilastatin 500 mg and relebactam 125 mg and 117 subjects with imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg), and 114 patients treated with imipenem 500 mg/cilastatin 500 mg, administered intravenously over 30 minutes every 6 hours for 4 to 14 days, at the discretion of the investigator. The mean age was 49 years, 23% of the patients were 65 years of age and older, 9.8% were 75 years of age and older, and 42% were female. Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation in Adult Patients In Trial 1, serious adverse reactions occurred in 27% (71/266) of patients receiving RECARBRIO and 32% (86/269) of patients receiving piperacillin and tazobactam. Adverse reactions leading to death were reported in 15% (40/266) of patients receiving RECARBRIO and 21% (57/269) of patients receiving piperacillin and tazobactam. Adverse reactions leading to discontinuation occurred in 5.6% (15/266) of patients receiving imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg and 8.2% (22/269) of patients receiving piperacillin and tazobactam. In Trials 2 and 3, serious adverse reactions occurred in 3.2% (7/216) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg and 5.1% (11/214) of patients receiving imipenem 500 mg/cilastatin 500 mg. There were no deaths reported in patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg alone. Deaths were reported in 1.4% (3/215) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 125 mg (not an approved dose). Adverse reactions leading to discontinuation occurred in 1.9% (4/216) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg and 2.3% (5/214) of patients receiving imipenem 500 mg/cilastatin 500 mg. Common Adverse Reactions in Adult Patients In Trial 1, adverse reactions occurred during the protocol-specified follow-up period, which was IV therapy plus 14 days following completion of therapy, in 85% (226/266) of patients receiving RECARBRIO and 87% (233/269) of patients receiving piperacillin and tazobactam. Table 5 lists the most common adverse reactions occurring in ≥4% of patients receiving imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg or piperacillin and tazobactam in Trial 1. Table 5: Adverse Reactions Occurring in Greater Than or Equal to 4% of HABP/VABP Adult Patients Receiving RECARBRIO in Trial 1 Adverse Reaction RECARBRIO RECARBRIO, IV every 6 hours. (N=266) N (%) Piperacillin/Tazobactam Piperacillin 4000 mg and Tazobactam 500 mg (4.5 grams), IV every 6 hours. (N=269) N (%) Blood and lymphatic system disorders Anemia 28 (10.5%) 27 (10.0%) Gastrointestinal disorders Constipation 11 (4.1%) 3 (1.1%) Diarrhea 21 (7.9%) 30 (11.2%) General disorders and administration site conditions Pyrexia 11 (4.1%) 20 (7.4%) Laboratory investigations Alanine aminotransferase increased 26 (9.8%) 19 (7.1%) Aspartate aminotransferase increased 31 (11.7%) 20 (7.4%) Metabolism and nutrition disorders Hypokalemia Hypokalemia includes hypokalemia and blood potassium decreased. 21 (7.9%) 26 (9.7%) Hyponatremia Hyponatremia includes hyponatremia and blood sodium decreased. 17 (6.4%) 3 (1.1%) Skin and subcutaneous tissue disorders Rash Rash includes rash, rash erythematous, and rash generalized. 11 (4.1%) 5 (1.9%) Less Common Adverse Reactions Reported in Trial 1 The following selected adverse reaction was reported in RECARBRIO-treated subjects at a rate of less than 4%: Blood and lymphatic system disorders: thrombocytopenia In Trials 2 and 3, adverse reactions occurred during the protocol specified follow-up period, which was IV therapy plus 14 days following completion of therapy, in 39% (85/216) of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg and 36% (77/214) of patients receiving imipenem 500 mg/cilastatin 500 mg. Table 6 lists the most common adverse reactions occurring in ≥1% of patients receiving imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg or imipenem 500 mg/cilastatin 500 mg in Trials 2 and 3. Table 6: Adverse Reactions Occurring in Greater Than or Equal to 1% of cUTI and cIAI Adult Patients Receiving Imipenem/Cilastatin plus Relebactam 250 mg or Imipenem/Cilastatin in Trials 2 and 3 Adverse Reaction Imipenem/Cilastatin and Relebactam 250 mg Imipenem/Cilastatin (500 mg/500 mg) + Relebactam (250 mg), IV every 6 hours. (N=216) N (%) IMI + Placebo Imipenem/Cilastatin (500 mg/500 mg) + Placebo, IV every 6 hours. (N=214) N (%) Blood and lymphatic system disorders Anemia Anemia includes anemia and hemoglobin decreased. 2 (1%) 4 (2%) Gastrointestinal disorders Diarrhea 12 (6%) 9 (4%) Nausea 12 (6%) 12 (6%) Vomiting 7 (3%) 4 (2%) General disorders and administration site conditions Phlebitis/Infusion site reactions Infusion site reactions include infusion site phlebitis, infusion site erythema, and infusion site pain. 5 (2%) 3 (1%) Pyrexia 5 (2%) 3 (1%) Laboratory Investigations Alanine aminotransferase increased 7 (3%) 4 (2%) Aspartate aminotransferase increased 6 (3%) 3 (1%) Lipase increased 3 (1%) 4 (2%) Blood creatinine increased 1 (<1%) 3 (1%) Nervous system disorders Headache 9 (4%) 5 (2%) Central nervous system adverse reactions Central nervous system adverse reactions include agitation, apathy, confusional states, delirium, disorientation, slow speech, and somnolence. 2 (1%) 5 (2%) Vascular disorders Hypertension Hypertension includes hypertension and blood pressure increased. 4 (2%) 6 (3%) Other Adverse Reactions Associated with Imipenem/Cilastatin Adverse reactions reported with imipenem/cilastatin, a component of RECARBRIO, in clinical studies or during post-marketing experience are listed below. These adverse reactions are not listed above for patients treated with RECARBRIO in Trial 1 or imipenem 500 mg/cilastatin 500 mg plus relebactam 250 mg in Trials 2 and 3. Blood and Lymphatic System Disorders : agranulocytosis, increased eosinophils, hemolytic anemia Nervous System Disorders: seizure Hepatobiliary Disorders : hepatic failure, jaundice Laboratory Investigations : blood lactate dehydrogenase increased, Coombs test positive, eosinophil count increased. Pediatric Patients Clinical Trial Experience in Pediatric Patients with HABP/VABP, cUTI and cIAI RECARBRIO was evaluated in an open-label, randomized, active-controlled, multi-dose, phase 2/3 clinical trial (Trial 4) in pediatric patients from birth to less than 18 years of age with HABP/VABP, cUTI or cIAI [see Clinical Studies (14.3) ]. A total of 85 patients were treated with RECARBRIO and 28 were treated with a comparator agent (investigator's choice from a specified list of comparators). RECARBRIO was administered intravenously as a weight-based dose of 37.5 mg/kg (imipenem 15 mg/kg, cilastatin 15 mg/kg, and relebactam 7.5 mg/kg) every 6 hours or 8 hours, or a fixed-dose of 1.25 grams (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) every 6 hours. In Trial 4, adverse reactions were comparable to those observed in adults. No patient died in either intervention group in the study through Day 28. The most common adverse reactions occurring in greater than 3% of pediatric patients receiving RECARBRIO were vomiting (15%), diarrhea (9%), nausea (7%), headache (6%), phlebitis/infusion site reactions (including phlebitis, infusion site phlebitis, infusion site extravasation, medical device site dermatitis; 5%), and rash (including rash, rash erythematous, rash maculopapular; 4%).

adverse reactions table

<table width="75%" ID="Table5"> <caption>Table 5: Adverse Reactions Occurring in Greater Than or Equal to 4% of HABP/VABP Adult Patients Receiving RECARBRIO in Trial 1</caption> <col width="50%" align="left" valign="middle"/> <col width="30%" align="center" valign="middle"/> <col width="20%" align="center" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule">Adverse Reaction</th> <th styleCode="Rrule">RECARBRIO<footnote ID="tb3f1">RECARBRIO, IV every 6 hours.</footnote> (N=266) N (%)</th> <th styleCode="Rrule">Piperacillin/Tazobactam<footnote ID="tb3f2">Piperacillin 4000 mg and Tazobactam 500 mg (4.5 grams), IV every 6 hours.</footnote> (N=269) N (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Blood and lymphatic system disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Anemia </td> <td styleCode="Rrule">28 (10.5%)</td> <td styleCode="Rrule">27 (10.0%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Constipation</td> <td styleCode="Rrule">11 (4.1%)</td> <td styleCode="Rrule">3 (1.1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea </td> <td styleCode="Rrule">21 (7.9%)</td> <td styleCode="Rrule">30 (11.2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">General disorders and administration site conditions</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pyrexia </td> <td styleCode="Rrule">11 (4.1%)</td> <td styleCode="Rrule">20 (7.4%) </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Laboratory investigations</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Alanine aminotransferase increased</td> <td styleCode="Rrule">26 (9.8%)</td> <td styleCode="Rrule">19 (7.1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Aspartate aminotransferase increased</td> <td styleCode="Rrule">31 (11.7%)</td> <td styleCode="Rrule">20 (7.4%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Metabolism and nutrition disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Hypokalemia<footnote ID="tb3f3">Hypokalemia includes hypokalemia and blood potassium decreased.</footnote> </td> <td styleCode="Rrule">21 (7.9%)</td> <td styleCode="Rrule">26 (9.7%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Hyponatremia<footnote ID="tb3f4">Hyponatremia includes hyponatremia and blood sodium decreased.</footnote> </td> <td styleCode="Rrule">17 (6.4%)</td> <td styleCode="Rrule">3 (1.1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Skin and subcutaneous tissue disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule Rrule"> Rash<footnote ID="tb3f5">Rash includes rash, rash erythematous, and rash generalized.</footnote> </td> <td styleCode="Rrule">11 (4.1%)</td> <td styleCode="Rrule">5 (1.9%)</td> </tr> </tbody> </table>

adverse reactions table

<table width="75%" ID="Table6"> <caption>Table 6: Adverse Reactions Occurring in Greater Than or Equal to 1% of cUTI and cIAI Adult Patients Receiving Imipenem/Cilastatin plus Relebactam 250 mg or Imipenem/Cilastatin in Trials 2 and 3</caption> <col width="50%" align="left" valign="middle"/> <col width="30%" align="center" valign="middle"/> <col width="20%" align="center" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule">Adverse Reaction</th> <th styleCode="Rrule">Imipenem/Cilastatin and Relebactam 250 mg<footnote>Imipenem/Cilastatin (500 mg/500 mg) + Relebactam (250 mg), IV every 6 hours. </footnote> (N=216) N (%)</th> <th styleCode="Rrule">IMI + Placebo<footnote>Imipenem/Cilastatin (500 mg/500 mg) + Placebo, IV every 6 hours.</footnote> (N=214) N (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Blood and lymphatic system disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Anemia<footnote>Anemia includes anemia and hemoglobin decreased.</footnote> </td> <td styleCode="Rrule">2 (1%)</td> <td styleCode="Rrule">4 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea</td> <td styleCode="Rrule">12 (6%)</td> <td styleCode="Rrule">9 (4%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Nausea</td> <td styleCode="Rrule">12 (6%)</td> <td styleCode="Rrule">12 (6%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Vomiting</td> <td styleCode="Rrule">7 (3%)</td> <td styleCode="Rrule">4 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">General disorders and administration site conditions</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Phlebitis/Infusion site reactions<footnote>Infusion site reactions include infusion site phlebitis, infusion site erythema, and infusion site pain.</footnote> </td> <td styleCode="Rrule">5 (2%)</td> <td styleCode="Rrule">3 (1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pyrexia</td> <td styleCode="Rrule">5 (2%)</td> <td styleCode="Rrule">3 (1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Laboratory Investigations</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Alanine aminotransferase increased</td> <td styleCode="Rrule">7 (3%)</td> <td styleCode="Rrule">4 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Aspartate aminotransferase increased</td> <td styleCode="Rrule">6 (3%)</td> <td styleCode="Rrule">3 (1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Lipase increased</td> <td styleCode="Rrule">3 (1%)</td> <td styleCode="Rrule">4 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Blood creatinine increased</td> <td styleCode="Rrule">1 (&lt;1%)</td> <td styleCode="Rrule">3 (1%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Nervous system disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Headache</td> <td styleCode="Rrule">9 (4%)</td> <td styleCode="Rrule">5 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Central nervous system adverse reactions<footnote>Central nervous system adverse reactions include agitation, apathy, confusional states, delirium, disorientation, slow speech, and somnolence.</footnote> </td> <td styleCode="Rrule">2 (1%)</td> <td styleCode="Rrule">5 (2%)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule"> <content styleCode="bold">Vascular disorders</content> </td> <td/> <td styleCode="Rrule"/> </tr> <tr> <td styleCode="Lrule Rrule"> Hypertension<footnote>Hypertension includes hypertension and blood pressure increased. </footnote> </td> <td styleCode="Rrule">4 (2%)</td> <td styleCode="Rrule">6 (3%)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.